Palvella Therapeutics

Also Clin3 microcystic lymphatic malformations, Clin2 Gorlin syndrome, Clin0 vascular malformations; PTX-014 Clin0 rare disease

Palvella Therapeutics is creating treatments for patients with genetic skin diseases. There are many challenges to topical delivery of drugs including skin penetration and the biochemical properties of the drug. Using their QTORIN platform, Palvella is overcoming these topical delivery challenges for a range of cargoes deep into the skin epidermis or dermis. Currently, Palvella has several programs, including QTORIN rapamycin 3.9$ and PTX-014 use the QTORIN technology to deliver the active cargo directly to the site of genetic pathology of each disease. Palvella’s approach has the potential to be applied for various drugs and diseases, including single agents or fixed combinations.

Jobs: